Bulk-Drug Compounding Companies, Market Entry and Expansion Strategies

Top Companies in the Bulk-Drug Compounding Market & Their Offering 2026

Fagron NV

Headquarter: Rotterdam, Netherlands
Offerings: Fagron supplies compounding products, raw materials, excipients, equipment, and sterile/non-sterile formulations to pharmacies, hospitals, and healthcare providers worldwide, supporting personalized medicine and compounding services.

B. Braun SE

Headquarter: Melsungen, Germany
Offerings: A major medical and pharmaceutical company offering a wide range of healthcare products, including infusion and injection systems, surgical instruments, hospital supplies, and devices for patient care and therapy.

Baxter International Inc.

Headquarter: Illinois, USA
Offerings: Provides medical supplies and therapies such as sterile IV solutions, infusion systems, parenteral nutrition, dialysis products, anesthesia, and critical care pharmaceuticals.

Fresenius Kabi AG

Headquarter: Homburg, Germany
Offerings: Specializes in life-saving medicines and technologies for infusion, transfusion, clinical nutrition, and IV generic drugs, serving critically and chronically ill patients globally.

QuVa Pharma, Inc.

Headquarter: Texas, USA
Offerings: Focuses on 503B sterile injectable compounding services for hospitals and health systems, offering ready-to-administer compounded medications and data/analytics solutions to optimize pharmacy operations.

Value Chain Analysis

R&D

• R&D in bulk drug compounding focuses on studying active pharmaceutical ingredients (APIs) and refining compounding techniques to modify, combine, or optimize drugs. It supports customized dosing, addresses drug shortages, and improves cost-efficient production methods.
• Key players: Fagron, Fresenius Kabi, Pfizer CentreOne, Hikma Pharmaceuticals, and Medisca.

Clinical Trials

• Clinical trials frequently depend on customized compounded formulations during early-stage development. Bulk drug substances are used to prepare trial-specific dosage forms, including capsules or liquid formulations, when suitable commercial products are unavailable.
• Key players: Catalent, Lonza, Thermo Fisher Scientific, Recipharm, and Piramal Pharma Solutions.

Formulation and Final Dosage Preparation

• Final dosage preparation in bulk drug compounding involves formulating patient-specific medicines by blending active pharmaceutical ingredients with suitable excipients or modifying FDA-approved drugs. This approach enables precise dosing, alternative dosage forms, and improved patient suitability when standard products are insufficient.
• Key players: QuVa Pharma, Nephron Pharmaceuticals, B. Braun Medical, Athenex Pharma Solutions, and Fagron.

Market Growth

The global bulk-drug compounding market size was estimated at USD 12.52 billion in 2025 and is predicted to increase from USD 13.18 billion in 2026 to approximately USD 20.87 billion by 2035, expanding at a CAGR of 5.24% from 2026 to 2035.

What are the Recent Developments in the Bulk-Drug Compounding Market? 

• In March 2025, Novo Nordisk signaled potential legal action against pharmacies producing compounded versions of Wegovy, highlighting growing intellectual property disputes between branded drug manufacturers and compounding pharmacies over unauthorized formulation and distribution
• In March 2025, Sycamore Partners announced a USD 10 billion acquisition proposal for Walgreens, indicating growing private-equity interest in leveraging and expanding in-store pharmacy and compounding capabilities to drive long-term value creation

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com